Poster

Robust Automated Leukapheresis Cryo-processing Enables High-quality Material for Both Autologous and Allogenic CAR T-cell Therapy Manufacturing

Adoptive cell therapy with chimeric antigen receptor (CAR) T cells has proven to be a highly effective treatment. Due to the logistical challenges, selecting the appropriate starting material for apheresis, whether fresh or frozen, is crucial in cell therapy. Understanding these differences is vital for optimizing the manufacturing process and ensuring the highest quality and efficacy of CAR T-cell products.

This poster explores how our Automated Closed Cryopreservation Process (ACP):

• Delivers consistent, compliant, high-quality cryopreserved leukapheresis starting materials
• Preserves cell viability and phenotype post-thawing
• Reduces operator-dependent variability and improves reproducibility
• Enables manufacturing flexibility and scheduling

Download the poster and discover how our platform enhances feasibility and efficiency for both autologous and allogenic CAR-T manufacturing pipelines.